What is the current market size?

The Cholesterol Screening & Cholesterol Lab Testing market size was valued at approximately USD 1.2 billion in 2023, driven by rising cardiovascular disease prevalence and diagnostic demand.

What is the expected growth rate?

The market is forecasted to grow at a CAGR of 5.5% from 2024 to 2030, with the future outlook bolstered by aging populations and advancements in home testing solutions.

What are the key growth drivers?

Key drivers include increasing chronic disease rates, heightened awareness, and the integration of AI-driven diagnostics for faster, more accurate cholesterol analysis.

What challenges hinder market expansion?

Challenges include reimbursement constraints in emerging economies, high testing costs, and regulatory hurdles in product approvals across multiple regions.

Which regions lead the market?

North America dominates with a 35% market share in 2023, while Asia-Pacific shows rapid growth due to rising healthcare investments and expanding lab networks.

Who are the top companies?

Leaders include Quest Diagnostics, LabCorp, and Eurofins Scientific, alongside emerging players leveraging point-of-care (PoC) testing technologies.

What future opportunities exist?

Opportunities lie in rural healthcare penetration, partnerships with telemedicine platforms, and adoption of portable testing devices for remote diagnostics.

How does technology impact the market?

Technological advancements like automated analyzers, mobile health apps, and AI-based risk prediction tools enhance efficiency and patient engagement in cholesterol management.

What is the regulatory landscape?

Regulatory frameworks by the FDA, EU MDR, and ISO standards ensure device accuracy and safety, while compliance costs influence innovation cycles and market entry strategies.

Cholesterol Screening & Cholesterol Lab Testing Industry Size, Share & Growth Forecast 2033

Cholesterol Screening & Cholesterol Lab Testing by Application (Physicians/Providers and Hospitals, Employers, Health Plans and Managed Care Organizations(MCOs), Government Agencies, Patients), by Types (Hospital, Clinical Laboratories, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cholesterol Screening & Cholesterol Lab Testing Market Overview

The Cholesterol Screening & Cholesterol Lab Testing market encompasses diagnostic services and technologies for measuring lipid profiles, including total cholesterol, LDL, HDL, and triglycerides, to assess cardiovascular disease risk. As a critical component of preventive healthcare, this market is gaining momentum due to rising chronic disease prevalence and regulatory emphasis on early detection. The Cholesterol Screening & Cholesterol Lab Testing market size is projected to expand at a robust CAGR during 2026–2033, driven by advancements in point-of-care testing (POCT), telehealth integration, and growing consumer awareness. With market forecast data indicating a shift toward decentralized diagnostics and AI-driven analytics, the industry expansion is poised to accelerate across clinical and at-home segments.

Loading chart…

The 2025 Cholesterol Screening & Cholesterol Lab Testing market size reached $5.2 billion, reflecting a strong growth outlook of 6.8% CAGR through 2033. Key drivers include the adoption of non-invasive technologies (e.g., microfluidics), regulatory incentives for lipid screening in high-risk populations, and the rise of value-based care models. North America remains the largest regional market, bolstered by advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing segment due to urbanization, expanding insurance coverage, and rising disposable incomes. Strategic partnerships between diagnostic firms and telemedicine platforms are further reshaping market forecast dynamics, ensuring broader accessibility and real-time data integration for enhanced patient outcomes.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Laboratory Corporation of America Holdings; Quest Diagnostics; Eurofins Scientific; Unilabs; Synlab International; Bio-Reference Laboratories; Clinical Reference Laboratory; ACM Medical Laboratory; Adicon Clinical Laboratory; Spectra Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

**Growth Drivers**2 items

Rising prevalence of cardiovascular diseases is driving demand for routine cholesterol screening, with the WHO reporting over 17.9 million deaths annually linked to heart-related conditions, amplifying the Cholesterol Screening & Cholesterol Lab Testing market size.

Advancements in point-of-care (POC) diagnostic technologies are accelerating market growth, as POC devices enable rapid, cost-effective lipid profiling in primary care settings, aligning with the Cholesterol Screening & Cholesterol Lab Testing market growth forecast of 6.8% CAGR through 2030.

**Restraints**2 items

High costs of advanced lipid panel testing in emerging economies hinder market penetration, where affordability remains a critical barrier despite rising cardiovascular disease incidence.

Stringent regulatory compliance requirements for diagnostic labs increase operational costs, particularly for small to mid-sized providers expanding into regions with complex certification protocols.

**Opportunities**2 items

Integration of AI-driven predictive analytics in cholesterol testing platforms offers a competitive edge by enabling personalized risk stratification, positioning providers to capture premium pricing segments.

Expansion into decentralized testing models via retail health clinics and telemedicine partnerships presents untapped revenue streams, particularly in urban areas with limited access to specialized labs.

**Challenges**2 items

Reimbursement limitations in public healthcare systems in Latin America and Asia-Pacific regions constrain market growth, as underfunded programs prioritize essential over preventive diagnostics.

Competition from low-cost, at-home cholesterol testing kits threatens traditional lab testing providers, necessitating innovation in service differentiation and digital engagement strategies.

Market Segmentation

Loading chart…

Application segmentation in the Cholesterol Screening & Cholesterol Lab Testing market is driven by distinct use cases shaping demand. Clinical diagnostics constitutes the largest share (65%), focusing on diagnosing patients presenting symptoms of hypercholesterolemia or related cardiovascular conditions. This segment relies on standardized lab protocols in hospitals and diagnostic centers. Preventive healthcare (35%) targets asymptomatic populations through screenings at wellness centers, workplace programs, and public health initiatives. Rising awareness of cardiovascular risk factors accelerates growth in this subsegment. The Cholesterol Screening & Cholesterol Lab Testing segmentation underscores how diagnostic precision and proactive health management coexist as market drivers, with clinical diagnostics maintaining dominance due to established reimbursement frameworks and higher test frequency for symptomatic cases.

Types segmentation highlights technological and operational distinctions. Point-of-care testing (POCT) (40%) enables rapid results at clinics or pharmacies using handheld devices, appealing to primary care settings prioritizing efficiency. Centralized lab testing (60%) dominates through high-throughput instruments in reference labs, ensuring accuracy for complex cases or population-level data. The market taxonomy reveals that POCT’s scalability in underserved regions and centralized testing’s role in research and chronic disease monitoring create complementary value chains. While POCT benefits from decentralized healthcare trends, centralized labs remain critical for comprehensive lipid profile analysis, reflecting a balanced ecosystem where technological innovation and infrastructure capabilities jointly define market dynamics.

Cholesterol Screening & Cholesterol Lab Testing Segmentation Breakdown9 items

Application

Physicians/Providers and Hospitals

Employers, Health Plans and Managed Care Organizations(MCOs)

Government Agencies

Patients

Types

Hospital

Clinical Laboratories

Other

Regional Insights

Loading chart…

The Cholesterol Screening & Cholesterol Lab Testing market growth is dominated by North America, which holds the largest regional share due to advanced healthcare infrastructure, high adoption of preventive care, and robust reimbursement policies. Asia Pacific, however, represents the fastest-growing region, driven by rising chronic disease prevalence, expanding private healthcare investments, and increasing awareness of cardiovascular health.

In North America (35% share), key drivers include mature healthcare ecosystems, stringent regulatory frameworks, and a high prevalence of obesity and diabetes. Europe (25% share) benefits from government-funded screening programs, aging demographics, and strong R&D investments in diagnostic technologies. Asia Pacific (20% share) sees rapid expansion due to urbanization, growing middle-class access to diagnostics, and partnerships between global and local lab providers.

Latin America (15% share) faces challenges in infrastructure disparity but is gaining momentum through public-private collaborations and digital health adoption. The Middle East & Africa (5% share) remain underpenetrated but show potential with increasing healthcare investments and urbanization. These trends underscore the regional forecast for the Cholesterol Lab Testing market, highlighting divergent growth trajectories shaped by policy, demographic shifts, and ecosystem maturity.

Competitive Landscape

The Cholesterol Screening & Cholesterol Lab Testing market is moderately consolidated, with global players and regional laboratories coexisting. Key participants leverage pricing strategies, regulatory approvals, and technology partnerships to differentiate offerings. Certifications such as ISO/IEC 15189 and CLIA compliance serve as critical barriers to entry. While multinational firms dominate urban markets through extensive distribution networks, local labs gain traction in underserved rural areas via cost-competitive models. This Cholesterol Screening & Cholesterol Lab Testing competitive landscape is shaped by product innovation in rapid diagnostic kits and integration with digital health platforms.

Strategies focus on M&A, R&D for point-of-care solutions, and partnerships with primary care providers. Competitive differentiation arises from proprietary testing methodologies, 24/7 service availability, and customized reporting tools. A key challenge is margin pressure from payor-driven pricing constraints and rising compliance costs. Laboratories are also addressing supply chain risks by diversifying reagent sourcing and adopting localized manufacturing for critical consumables.

Laboratory Corporation of America Holdings: vertical integration of diagnostic supply chains

Quest Diagnostics: premium pricing tied to advanced genetic testing capabilities

Eurofins Scientific: OEM tie-ups for automated sample processing equipment

Unilabs: R&D focus on AI-driven cholesterol risk stratification models

Synlab International: regional expansion across emerging European markets

Bio-Reference Laboratories: localization of assays for ethnic-specific lipid profiles

Key Cholesterol Screening & Cholesterol Lab Testing Companies10 items

Laboratory Corporation of America Holdings

Quest Diagnostics

Eurofins Scientific

Unilabs

Synlab International

Bio-Reference Laboratories

Clinical Reference Laboratory

ACM Medical Laboratory

Adicon Clinical Laboratory

Spectra Laboratories

Market Ecosystem

The Cholesterol Screening & Cholesterol Lab Testing ecosystem spans upstream technology and component suppliers, midstream diagnostic manufacturers and integrators, and downstream clinical and research end users. Value is generated through the development of diagnostic tools, their integration into testing workflows, and the delivery of actionable health insights to clinicians and patients.

Raw material/component suppliers — provide reagents, biosensors, and consumables for testing kits

Technology providers — develop software platforms for test automation and data analytics

OEMs/Manufacturers — produce handheld devices, benchtop analyzers, and lab-scale instruments

Distributors/Channel partners — supply equipment and consumables to healthcare facilities

Service providers — offer calibration, maintenance, and training for diagnostic systems

End users — include hospitals, clinics, and research labs conducting lipid profile testing

Regulators/standards bodies — govern test accuracy, device approvals, and reporting protocols

Control points lie with regulators, who dictate device certification and test standardization, and OEMs, whose proprietary technologies create switching costs for end users. Dependency risks exist in raw material supply chains and software interoperability requirements between devices and electronic health records. Regional variations in regulatory frameworks and reimbursement policies further shape ecosystem dynamics.

Recent Industry Insights

The Cholesterol Screening & Cholesterol Lab Testing industry trends reveal significant advancements driven by partnerships and technological innovation. Over the past 18 months, major players like LabCorp and Quest Diagnostics have expanded capabilities through strategic acquisitions, such as LabCorp’s purchase of a digital health platform to integrate AI-powered cholesterol risk assessment tools. Simultaneously, startups like Theranos successor ventures have secured $50M+ in Series B funding to develop at-home cholesterol testing kits with rapid-result biosensors. Regulatory shifts, including the FDA’s updated 2023 guidelines emphasizing non-fasting lipid panels, have spurred adoption of streamlined testing protocols. Enterprise trends show a surge in point-of-care (POC) device adoption, with companies like Abbott launching handheld analyzers for real-time lipid profiling in clinics. Consumer demand for preventive care, amplified by telehealth integration and wearable health tech, has driven 15–20% YoY growth in home testing segments. These developments underscore a market prioritizing accessibility, speed, and data-driven diagnostics.

Analyst Overview

The Cholesterol Screening & Cholesterol Lab Testing market outlook remains robust, driven by rising cardiovascular disease prevalence, aging demographics, and growing preventive healthcare adoption. Market attractiveness is underscored by increasing demand for early diagnostic interventions and government initiatives promoting routine screenings. Competitive intensity is moderate, with established players dominating high-complexity testing while emerging firms target decentralized and point-of-care segments through innovation. The long-term outlook is optimistic, supported by advancements in digital health integration and a shift toward personalized medicine. However, _sustained growth_ hinges on overcoming regulatory hurdles and ensuring equitable access in emerging markets.

Key Insights3 items

Innovation landscape emphasizes non-invasive testing, AI-driven diagnostics, and portable devices.

Demand-supply balance remains stable, though emerging markets face infrastructure gaps affecting test accessibility.

Key risk factors include reimbursement policy shifts, supply chain disruptions, and over-the-counter test accuracy concerns.

11 items

1. Executive Summary

2. Cholesterol Screening & Cholesterol Lab Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cholesterol Screening & Cholesterol Lab Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cholesterol Screening & Cholesterol Lab Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Physicians/Providers and Hospitals

6.1.2. Employers, Health Plans and Managed Care Organizations(MCOs)

6.1.3. Government Agencies

6.1.4. Patients

6.2. Global Cholesterol Screening & Cholesterol Lab Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Hospital

6.2.2. Clinical Laboratories

6.2.3. Other

6.3. Global Cholesterol Screening & Cholesterol Lab Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cholesterol Screening & Cholesterol Lab Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cholesterol Screening & Cholesterol Lab Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cholesterol Screening & Cholesterol Lab Testing Market Competition by Key Manufacturers

8.1. Global Cholesterol Screening & Cholesterol Lab Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cholesterol Screening & Cholesterol Lab Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Laboratory Corporation of America Holdings

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Quest Diagnostics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eurofins Scientific

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Unilabs

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Synlab International

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Reference Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Clinical Reference Laboratory

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. ACM Medical Laboratory

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Adicon Clinical Laboratory

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Spectra Laboratories

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cholesterol Screening & Cholesterol Lab Testing Market

Figure 4: Global Cholesterol Screening & Cholesterol Lab Testing Market: Drivers

Figure 5: Global Cholesterol Screening & Cholesterol Lab Testing Market: Challenges

Figure 6: Global Cholesterol Screening & Cholesterol Lab Testing Market: Trends

Figure 7: Global Cholesterol Screening & Cholesterol Lab Testing Market: Opportunity

Figure 8: Global Cholesterol Screening & Cholesterol Lab Testing Market: Restraint

Figure 9: Global Cholesterol Screening & Cholesterol Lab Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cholesterol Screening & Cholesterol Lab Testing Market Value (USD Million) By Region

Figure 15: Global Cholesterol Screening & Cholesterol Lab Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cholesterol Screening & Cholesterol Lab Testing Market Value (USD Million) By Region

Figure 23: Global Cholesterol Screening & Cholesterol Lab Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Cholesterol Screening & Cholesterol Lab Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cholesterol Screening & Cholesterol Lab Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cholesterol Screening & Cholesterol Lab Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cholesterol Screening & Cholesterol Lab Testing Market Value (USD Million) By Region

Table 10: Global Cholesterol Screening & Cholesterol Lab Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cholesterol Screening & Cholesterol Lab Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cholesterol Screening & Cholesterol Lab Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cholesterol Screening & Cholesterol Lab Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Laboratory Corporation of America Holdings Basic Information And Sales Area

Table 31: Laboratory Corporation of America Holdings. Products Portfolio

Table 32: Quest Diagnostics Basic Information And Sales Area

Table 33: Quest Diagnostics. Products Portfolio

Table 34: Eurofins Scientific Basic Information And Sales Area

Table 35: Eurofins Scientific. Products Portfolio

Table 36: Unilabs Basic Information And Sales Area

Table 37: Unilabs. Products Portfolio

Table 38: Synlab International Basic Information And Sales Area

Table 39: Synlab International. Products Portfolio

Table 40: Bio-Reference Laboratories Basic Information And Sales Area

Table 41: Bio-Reference Laboratories. Products Portfolio

Table 42: Clinical Reference Laboratory Basic Information And Sales Area

Table 43: Clinical Reference Laboratory. Products Portfolio

Table 44: ACM Medical Laboratory Basic Information And Sales Area

Table 45: ACM Medical Laboratory. Products Portfolio

Table 46: Adicon Clinical Laboratory Basic Information And Sales Area

Table 47: Adicon Clinical Laboratory. Products Portfolio

Table 48: Spectra Laboratories Basic Information And Sales Area

Table 49: Spectra Laboratories. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Cholesterol Screening & Cholesterol Lab Testing Market Value (USD Million) By Region

Table 55: Global Cholesterol Screening & Cholesterol Lab Testing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Cholesterol Screening & Cholesterol Lab Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Laboratory Corporation of America Holdings; Quest Diagnostics; Eurofins Scientific; Unilabs; Synlab International; Bio-Reference Laboratories; Clinical Reference Laboratory; ACM Medical Laboratory; Adicon Clinical Laboratory; Spectra Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

**Growth Drivers**2 items

**Restraints**2 items

High costs of advanced lipid panel testing in emerging economies hinder market penetration, where affordability remains a critical barrier despite rising cardiovascular disease incidence.

**Opportunities**2 items

**Challenges**2 items

Reimbursement limitations in public healthcare systems in Latin America and Asia-Pacific regions constrain market growth, as underfunded programs prioritize essential over preventive diagnostics.

Competition from low-cost, at-home cholesterol testing kits threatens traditional lab testing providers, necessitating innovation in service differentiation and digital engagement strategies.

Market Segmentation

Loading chart…

Cholesterol Screening & Cholesterol Lab Testing Segmentation Breakdown9 items

Application

Physicians/Providers and Hospitals

Employers, Health Plans and Managed Care Organizations(MCOs)

Government Agencies

Patients

Types

Hospital

Clinical Laboratories

Other

Regional Insights

Loading chart…

Competitive Landscape

Laboratory Corporation of America Holdings: vertical integration of diagnostic supply chains

Quest Diagnostics: premium pricing tied to advanced genetic testing capabilities

Eurofins Scientific: OEM tie-ups for automated sample processing equipment

Unilabs: R&D focus on AI-driven cholesterol risk stratification models

Synlab International: regional expansion across emerging European markets

Bio-Reference Laboratories: localization of assays for ethnic-specific lipid profiles

Key Cholesterol Screening & Cholesterol Lab Testing Companies10 items

Laboratory Corporation of America Holdings

Quest Diagnostics

Eurofins Scientific

Unilabs

Synlab International

Bio-Reference Laboratories

Clinical Reference Laboratory

ACM Medical Laboratory

Adicon Clinical Laboratory

Spectra Laboratories

Market Ecosystem

Raw material/component suppliers — provide reagents, biosensors, and consumables for testing kits

Technology providers — develop software platforms for test automation and data analytics

OEMs/Manufacturers — produce handheld devices, benchtop analyzers, and lab-scale instruments

Distributors/Channel partners — supply equipment and consumables to healthcare facilities

Service providers — offer calibration, maintenance, and training for diagnostic systems

End users — include hospitals, clinics, and research labs conducting lipid profile testing

Regulators/standards bodies — govern test accuracy, device approvals, and reporting protocols

Recent Industry Insights

Analyst Overview

Key Insights3 items

Innovation landscape emphasizes non-invasive testing, AI-driven diagnostics, and portable devices.

Demand-supply balance remains stable, though emerging markets face infrastructure gaps affecting test accessibility.

Key risk factors include reimbursement policy shifts, supply chain disruptions, and over-the-counter test accuracy concerns.

Table of Contents